Lectus Therapeutics Ltd, which develops next-generation ion channel modulators, announced it will move its corporate headquarters and research facility to the Babraham Research Campus in Cambridge.
Originally based in Bristol, the firm will now run all research operations as well as commercial and financial activities from the new location, the the company says is an important part of its strategy to develop a ‘robust infrastructure to reflect the growth of its research and development activities’ following its successful £8.2m Series A financing earlier this year.
In April, the company acquired NeuroServe Ltd., an electrophysiology company with research facilities important in the development of Lectus’ ion channel modulators.
“Lectus’ move to the new facility at the Babraham Research Campus represents the next step in the implementation of our strategy for growth,” said Dr Roland Kozlowski, chief executive officer of Lectus.
“With this move, we will benefit from improved research facilities and exceptional local infrastructure and will be in an excellent position to progress our next-generation ion channel drugs, for treatment of pain and urinary incontinence, towards the clinic.”
© Crimson Business Ltd. 2006
